 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 1402836-58-1 |
| Molecular formula(MF) | C18H22N2O |
| Molecular Weight(MW): | 282.38 |
| Alias |
| In vitro | Ethanol | 30 mg/mL (106.23 mM) |
|---|---|---|
| DMSO | 15 mg/mL warmed (53.11 mM) | |
| Water | <1 mg/mL | |
| In vivo |
| Description | NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
NLG919 potently blocks IDO-induced T-cell suppression and restored robust T-cell responses with ED50 of 80 nM. Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I) in vitro, with ED50 of 120 nM. [1] |
||
| In vivo | In mice, a single oral administration of NLG919 reduces the concentration of plasma and tissue Kyn by ~ 50%. In mice bearing B16F10 tumors, NLG919 markedly enhances the antitumor responses of naive, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA.[1] |